Corporate Presentation June 26, 2023 Exhibit 99.1

Forward-looking statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. Examples of such statements include, but are not limited to, statements about plans for the commercialization of OLPRUVA™ for oral suspension in the U.S. for the treatment of certain patients with UCDs involving deficiencies of CPS, OTC, or AS, including negotiations with commercial payers and Medicaid organizations regarding access as well as the timing of drug availability and the expected commercial launch, statements about plans and potential milestones for the continued clinical development of OLPRUVA™ in other indications, statements about plans and potential milestones for the continued clinical development of EDSIVO™ for treatment of vEDS in patients with a confirmed type III collagen (COL3A1) mutation, statements about plans for the development of ACER-801, statements about our anticipated 2023 milestones, and statements about our capital requirements and sufficiency and duration of our current cash and cash equivalents. Our efforts to commercialize OLPRUVA™ for oral suspension in the U.S. for the treatment of certain patients with UCDs involving deficiencies of CPS, OTC, or AS are at an early stage, we currently do not have fully developed marketing, sales or distribution capabilities, and there is no guarantee that we will be successful in our commercialization efforts.  Our pipeline products (including OLPRUVA™ for indications other than UCDs as well as EDSIVO™ and ACER-801) are under investigation and their safety and efficacy have not been established and there is no guarantee that any of our investigational products in development will receive health authority approval or become commercially available for the uses being investigated. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the availability of financing to fund our commercialization efforts, our pipeline product development programs and our general corporate operations as well as risks related to drug development and the regulatory approval process, including the timing and requirements of regulatory actions. We disclaim any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. You should review additional disclosures we make in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. You may access these documents for no charge at http://www.sec.gov.

Provide transformative treatments with a human touch to underserved or overlooked patients with rare and life-threatening diseases Identify and develop treatments where science can be applied in new ways for use in diseases with high unmet need Develop and deliver life -changing therapies to patients quickly and efficiently The Acer story Our Mission Our Difference Our Goal Acer is a pharmaceutical company that acquires, develops and commercializes therapies for serious rare and life-threatening diseases with significant unmet medical needs

Acer Management team Chris schelling Chief Executive officer & Founder Adrian quartel, md Chief medical officer Harry palmin Chief financial officer Bernie paul Chief people officer Don joseph, Jd Chief legal officer John klopp Chief technical officer Tanya hayden Chief operating officer Jeff davis Chief business officer

Program Indication Phase 1 Phase 2 Phase 3 Approved Expected Milestones Urea Cycle Disorders1 Approved in US; drug availability anticipated early July 2023$ EDSIVO™ (celiprolol) Vascular Ehlers-Danlos Syndrome (COL3A1+) H1 2024: Full trial enrollment$ Commercial and late-stage pipeline 1 OLPRUVA™ (sodium phenylbutyrate) for oral suspension approved in the U.S. for the treatment of certain patients living with urea cycle disorders (UCDs) involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS) $ Subject to additional capital

Full Prescribing Information: https://www.acertx.com/OLPRUVA/PI.pdf OLPRUVATM (sodium phenylbutyrate) for oral suspension

highlights $ Subject to additional capital 1 https://www.clinicaltrials.gov/study/NCT01948427?term=thrive%20study%20horizon&rank=1 2 Data on file 3 https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-reports-first-quarter-2023-financial 4 https://www.das.nh.gov/hr/documents/health_benefits/2023-Drug-List-Exclusion-Changes-Eff-07012023.pdf OLPRUVA™ is a commercial-ready, novel formulation of phenylbutyrate with convenient, single-dose packaging FDA approved in December 2022, patent protection through 2036 Dual-coated formulation delays release in water for up to 5-minutes, rapidly dissolves in acidic environment (e.g., stomach) Multiple opportunities for potential indication expansion for OLPRUVA™ franchise:$ UCD investigations to determine whether it’s possible to: enhance administration flexibility options; improve bioavailability via pre-meal administration Other investigational indications: MSUD, liver disorders Area of High Unmet Need (Urea Cycle Disorders) Currently, phenylbutyrate is prescribed for ~800 patients with UCDs In real world setting, neither Ravicti® nor Buphenyl® maintain ammonia levels below ULN in long-term follow-up of UCD patients1 Palatability, odor, preparation, route of administration and packaging are listed as the most important attributes for UCD treatment adherence2 Adherence can also be affected when patients skip their mid-day dose, because existing treatments are inconvenient to take to work or school2 Commercial Opportunity Significant revenue opportunity for phenylbutyrate: Net revenue of Ravicti® & Buphenyl®: $333M in FY 2022 and $91.7M in Q1 20233 Forecasted patient potential for OLPRUVA™: 250-350 patients (base case) Convenient and cost-advantageous alternative to Ravicti® OLPRUVA™’s wholesale acquisition cost (WAC) price (per gram) 50% lower than Ravicti®’s Ravicti® will be moved to “Excluded Medications” list on Express Script’s National Preferred Formulary starting 7/1/20234

UCDs: DISEASE Overview Urea Cycle Disorders (UCDs) are a group of rare, genetic disorders caused by mutations that result in a deficiency of one of the six enzymes or two transporters of the urea cycle These enzymes are responsible for removing ammonia from the bloodstream Reproduced from:   http://upload.wikimedia.org/wikipedia/commons/7/76/Symptoms_of_hyperammonemia.svg. Elevated ammonia levels in both symptomatic and asymptomatic patients can be neurotoxic leading to neurocognitive damage, among other symptoms Symptoms of Hyperammonemia General – Growth retardation – Hypothermia Central – Combativeness – Lethargy – Coma Eyes – Papilledema Pulmonary – Shortness of breath Liver – Enlarge-ment Muscular/Neurologic – Poor coordination – Dysdiadochokinesia – Hypotonia or hypertonia – Ataxia – Tremor – Seizures – Decorticate or decerebrate posturing Cytoplasm Mitochondrion Glutamate HCO3+NH4+2ATP CPS1 NAGS N-acetylglutamate (CPS1 cofactor) Carbamyl Phosphate OTC Ornithine Citrulline Carbamyl Aspartate Orotic Acid Urea ARG Arginine ASS Argininosuccinate ASL Fumarate H2O A healthy urea cycle converts ammonia into urea, which is excreted from the body. With a Urea Cycle Disorder (UCD), ammonia is not converted to urea, and ammonia builds up in the body. Ammonia enters the liver NAGS = N-acetylglutamate synthase CPS1 = Carbamoyl phosphate synthase OTC = Ornithine transcarbamylase AS = Argininosuccinate synthase AL = Argininosuccinate lyase ARG = Arginase

UCDs: Mechanism of action Nitrogen Binding Agents Alternative pathway treatment diverts nitrogen from the urea cycle to alternate routes of excretion Nitrogen binding agents, containing phenylbutyrate, are all metabolized to phenylacetate (PAA) PAA is the active moiety – it combines with glutamine, producing phenylacetylglutamine (PAGN) PAGN is then excreted by the kidneys in the urine Berry S, et al. Molecular Genetics and Metabolism 125 (2018) 251–257. NH4+ α-Ketoglutarate Glutamate Glutamine PAGN Nitrogen Binding Agents β-oxidation PAA Urine Excretion Fig. 1. Metabolizing pathway and mechanism of action of GPB. GPB (glycerol phenylbutyrate); PAA (phenylacetic acid); PBA (phenylbutyric acid); PAGN (phenylacetylglutamine).

Unmet need – efficacy THRIVE Observational study1 collected data on patients with UCDs Over first three years of follow-up, patients on both Ravicti® (GPB) and Buphenyl® (NaPB): Had mean ammonia levels ≥ Upper Limit of Normal (ULN) Comparable percentage of patients had a hyperammonemic crisis in both treatment groups 1 https://www.clinicaltrials.gov/study/NCT01948427?term=thrive%20study%20horizon&rank=1 Percentage of Participants With Hyperammonemic Crisis (mean overall duration on study was 1187.7 days) Baseline 1 6 12 18 24 30 36 months NaPB GPB Normal Treatment 42.00% 37.3% 0% 10% 20% 30%40% 50% 60% 70% 80% 90% 100%

Mean Relative Attribute Importance for UCD Treatment Adherence in a Discrete Choice Exercise1,2 1 ACER-sponsored, IRB-approved quantitative research study employing discrete choice study design. 2 Data on file. Qualitative Interviews with Leading UCD Centers Uncovered the Mid-Day Dose as a Driver of Poor Adherence in UCD patients2 UCD Expert Insights: “Skipping doses seems to increase with age, especially at mid-day” “Very common to skip dose” “Teenagers seem to struggle most” “Skipping mid-day dose happens all the time” Unmet need – treatment adherence Taste and Odor Weight Requirement Preparation Instructions Route of Administration Packaging Measurement 24% 21% 18% 17% 11% 9% 0% 5% 10% 15% 20% 25%

NOVEL Formulation OLPRUVA™ is a proprietary and novel formulation of NaPB powder that has shown bioequivalence to existing NaPB powder but with a pH-sensitive polymer coating that is designed to minimize dissolution of the coating for up to 5 minutes after preparation1 Polymer Coat(inactive pH-sensitive polymer) Designed to minimize dissolution of the coating for up to 5 minutes after preparation Drug Layer(NaPB) Delivers the proven ammonia control of NaPB powder1 Seal Coat (inactive ingredients) Seed Core(inactive core) 1 Acer Therapeutics. Data on File. 2021.

Nitrogen Scavenger Differentiation1 Phenylbutyrate Formulations OLPRUVA™ Ravicti® Buphenyl® Pheburane® Efficacy / Safety in UCDs ✓ ✓ ✓ ✓ Formulation Dual-coated oral pellets Clear Oily Liquid Powder or Tablets Single-coated oral pellets Palatability Up to 5 minutes Tasteless Bitter Taste Up to 10 seconds Packaging Single-dose Envelopes Glass vials with syringe for each dose Tub of powder or pills Large bottle of pellets Portability2 + + + - + Administration Mix with water and Mix-Aid Meter dose into syringe from glass vial Measure powder and mix with water or take up to 40 tablets per day Pour directly into mouth or sprinkle on each bite of apple sauce or carrot puree 1 No head-to-head studies have been conducted with OLPRUVA™ and any of the other products named, other than the bioequivalence study vs NaPB powder undertaken for 505(b)(2) pathway 2 Trinity Health Partners June 2022 Ravicti®, Buphenyl®, Pheburane® information sourced from prescribing information OLPRUVA™, Ravicti®, Buphenyl®, and Pheburane® are the registered trademarks of their respective owners

Commercial Strategy Unmet need and desire for new treatment options OLPRUVA™ is differentiated, dual coated, packaged in portable single dose envelopes Robust patient services program to support patients & caregivers Customized exclusive pharmacy approach to facilitate patient access to care Best in class team of rare disease professionals with deep relationships in UCD centers Commercial Launch Strategy$ = Positive Patient Experience + Exceptional Support NAVIGATOR by acertherapeutics $ Subject to additional capital

DISRUPTING AN ESTABLISHED UCD MARKET in U.S. Projected Prevalence1 ~ 2,100 Diagnosed Patients2 ~ 1,100 Patients Treated with Phenylbutyrate2 (Ravicti®, Buphenyl®, generics) ~ 800 Market share for nitrogen binding agents2 ~ 85% Ravicti® ~ 15% Buphenyl® or generic NaPB Ravicti® & Buphenyl® U.S. Net Revenue3 FY 2022: $333M Q1 2023: $91.7M 1 https://www.drugs.com/slideshow/top-10-most-expensive-drugs-1274 2 HealthVerity Payer claims data analysis 3 https://ir.horizontherapeutics.com

OLPRUVA™ Price & Reimbursement Acer believes pricing strategy will offer UCD patients a new treatment option at an approximately 50% discount to the current WAC price per gram of Ravicti® OLPRUVA™ pricing strategy informed by thorough market research and input received from advocacy organizations, focus groups, key opinion leaders and representatives from top U.S. commercial and government payers OLPRUVA™ wholesale acquisition cost (WAC) price submitted to the compendia WAC price now available in the major drug databases such as Redbook, Medispan, and First Data Bank Acer is not currently providing guidance on anticipated number of patients treated, net revenue and operating expenses.

Acer intends to explore additional lifecycle opportunities for OLPRUVA™ (sodium phenylbutyrate) in various disorders where clinical proof of concept data exists$: Maple Syrup Urine Disease (MSUD) Pyruvate Dehydrogenase Complex Deficiency (PCDC) Rare pediatric epilepsies Various liver disorders Lifecycle Opportunities $ Subject to additional capital

Intellectual property and exclusivity Orange Book Listed Patents: US Pat. Nos. 11,154,521 and 11,433,041 directed to formulations/compositions of matter US Pat. No. 11,202,767 directed to methods of use (UCD) Expiration date for OB patents is 10/17/2036 MSUD US Pat. Nos. 9,078,865 and 10,092,532 directed to methods of decreasing branched chain acids or MSUD Licensed from Baylor College of Medicine Expiration date is 7/26/2030 Combination with Benzoate US Pat. No. 11,517,547 directed to a kit comprising a combination therapeutic product composed of sodium phenylbutyrate or glycerol phenylbutyrate and sodium benzoate Licensed from Baylor College of Medicine Expiration date is 6/28/2038 Continuing to pursue new patents and exclusivity possibilities, based on development plans and product attributes

A selective adrenergic modulator (SAM) for the potential treatment of patients with COL3A1-positive vascular Ehlers-Danlos Syndrome (vEDS) (celiprolol) EDSIVOTM

VASCULAR EHLERS-DANLOS SYNDROME COL3A1+ vEDS Prevalence: Between 5,000 to 10,000 COL3A1+ vEDS patients in US5 Median US Survival: 51 years of age1 Risk: Arterial rupture or dissection events occur in ~25% of patients before the age of 20, but increase to ~90% of patients by age 401 1 Pepin, et al. Survival is affected by mutation type and molecular mechanism in vascular Ehlers–Danlos syndrome (EDS type IV). Genet Med. 2014 Dec;16(12):881-8. 2 https://www.ehlers-danlos.com/celiprolol-and-veds/ 3 Ong K, et al. Lancet 2010; 376: 1476-84. 4 Frank M, et al. Vascular Ehlers-Danlos Syndrome: Long-Term Observational Study. J Am Coll Cardiol. 2019 Apr, 73 (15) 1948–1957 5 Truven MarketScan database and U.S. population data Autosomal dominant connective tissue disorder of collagen synthesis caused by mutations in the COL3A1 gene for type III procollagen Characterized by arterial aneurysms, dissections and/or ruptures in arteries and hollow organs (intestines, uterus, lungs, etc.) Disease Overview No approved therapeutic options for vascular Ehlers-Danlos Syndrome (vEDS) patients Following the publication of the BBEST trial, celiprolol has become the primary treatment for vEDS patients in several European countries2 UNMET NEED Opportunity Efficacy data from BBEST clinical trial showing reduction in risk of arterial events observed in COL3A1+ subpopulation3 Additional data from long-term observational study in France4 DiSCOVER Phase 3 decentralized (virtual) pivotal trial ongoing with Breakthrough Therapy Designation, Special Protocol Assessment New Chemical Entity w/Orphan Drug Designation Patent protection until 2038

BBEST Trial: COL3A1+ Subpopulation Primary Endpoint Primary + Secondary Endpoints 0 12 24 36 48 60 72 Number at risk/events Celiprolol Control 13 13/1 12/2 9/2 8/2 2/2 20 19/2 15/6 11/9 4/11 3/11 11/3 9/3 8/3 2/3 16/5 9/12 6/14 3/14 2/14 p=0.0406 p=0.0167 time (months) Figure 3: Kaplan-Meier curves of event-free survival in 33 patients with positive COL3A1 mutation Primary endpoint (A). Primary and secondary endpoints (B). A B Proportion of survival free events (%) 0 12 24 36 48 60 72 25 50 75 100 Efficacy: 18 months to reach dose > 300 mg 76% reduction in the risk of fatal or nonfatal cardiac or arterial events in COL3A1+ EDSIVO™ patients vs. control group over mean follow-up of 47 months 75% reduction in risk of primary (cardiac or arterial events) and secondary (intestinal or uterine rupture) events in COL3A1+ EDSIVO™ patients vs. control group Ong Lancet 2010; 376: 1476-84.

Statistically-significant Efficacy: Between 2000 and 2017, 144 patients (100% COL3A1+) were included in this study Patients were normotensive (A) Patients not treated with celiprolol had a significantly worse survival outcome than treated patients: Overall survival was 80.7% (95% CI: 67.8% to 93.6%) in those treated with celiprolol (n = 110) versus 48.5% (95% CI: 19.7% to 77.4%) in those not treated (n = 22) after 11.1 years of follow-up: p = 0.0002 (B) Survival was significantly improved in patients taking celiprolol 400 mg/day compared with patients taking lower doses, suggesting a dose effect and that 400 mg/day should be considered the optimal treatment dose: At the end of follow-up, survival was 85% (95% CI: 70.5% to 99.5%) in those patients treated with celiprolol 400 mg/day and 69.2% (95% CI: 41.4% to 97.0%) in those taking celiprolol 100 to 300 mg/day: p = 0.035 Statistically significant decreases in hospitalization rates on intra-patient basis pre-and post-celiprolol treatment Long-Term Observational Study (French Cohort) Frank et al., J Am Coll Cardiol. 2019 Apr 23;73(15):1948-1957. Baseline characteristics BMI, kg/m2 21.2 (19.0-23.7) 21.0 (19.0-23.0 22.9 (20.5-26.1) 22.6 (17.3-28.4) 20.6 (19.0-22.5) 0.2415 SBP, mm Hg 114.0 (106.0-123.0) 113.0 (105.0-121.0) 120.0 (112.0-126.0) 112.5 (107.0-131.0) 113.5 (104.0-120.0) 0.2145 DBP, mm Hg 70.0 (65.0-78.0) 70.0 (64.0-76.0) 74.0 (65.0-83.0) 75.0 (68.0-85.0) 69.0 (68.0-76.0) 0.2837 Figure 3 Kaplan-Meier Survival Analysis of vEDS Patients in Groups I and II COL3A1 Pathogenic Variants, According to Celiprolol Treatment A Proportion Still Living 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 0 2 4 6 8 10 12 14 16 18 20 22 Log Rank p = 0.0002 Follow-Up (Year) Others Treated by Celiprolol B p = 0.035 400 mg/day <400 mg/day

pivotal phase 3 trial: enrolling patients $ Additional capital required to conduct and complete the planned pivotal Phase 3 trial of EDSIVO™ beyond Q4 2022 Decentralized Study of Celiprolol on vEDS-related Event Reduction (DiSCOVER) Trial A Phase 3, U.S.-based, randomized, double-blind, decentralized (virtual) clinical trial to compare the efficacy of celiprolol to placebo in the treatment of patients with COL3A1-positive vEDS Primary objective: compare time to first occurrence of a confirmed clinical event between celiprolol group and placebo group among confirmed COL3A1-positive vEDS patients Secondary objectives: Safety and tolerability of celiprolol Incidence rate of composite endpoint among vEDS patients treated with celiprolol vs. placebo EDSIVO™ Program Status Granted Breakthrough Therapy designation (BTD) by FDA Reached agreement with FDA on critical elements of protocol design under a Special Protocol Assessment (SPA) Launched discoverceliprolol.com as an educational tool for interested parties Initiated pivotal DiSCOVER trial (study NCT05432466) H1 2024: Full enrollment anticipated based on current enrollment rates$ Double-blind portion of trial intended to end if statistical significance is reached at an interim analysis (occurs at 28 vEDS-related events) Estimated to occur as early as approximately 18 months after completion of full enrollment, or after 46 vEDS-related clinical events$

Intellectual property and Exclusivity Patents Title: Method of Providing Celiprolol Therapy to a Patient Issued patent #11,523,997 – approximate expiration 12/2038 Claims direct to methods of treating vEDS Priority date is 12/21/2017 Assigned to AP-HP and Université Paris Descartes – Acer has exclusive license Pending in AR, BR, CA, & MX Orphan Drug – 7 years Bars FDA from approving any other application (ANDA, 505(b)(2) or “full” NDA or BLA) for the same drug for the same orphan disease or condition for 7 years, unless FDA finds that the applicant has shown clinical superiority Covered under the Orphan Drug Act and 21 CFR 316.31 New Chemical Entity – 5 years 5 years from the date of approval of the first approved NDA Pediatric exclusivity Additional 6 months to existing patents/exclusivity Pediatric exclusivity takes on characteristics of five-year, three-year or orphan exclusivity when it attaches to those protections Described in the Best Pharmaceuticals for Children Act (BCPA) and Section 505(A) of the Food and Drug Administration Modernization Act of 1997 1 pending trademark family EDSIVO™ Registered in BR, CA Pending in US

Financial overview Capitalization as of June 22, 2023 CASH POSITION as of march 31, 2023 $6.4M +$0.4M gross proceeds from ATM sales in Q2 2023 +$1.0M gross proceeds from promissory note with Chris Schelling, CEO & Founder* Cash runway into early Q3 2023 24.5M Shares of common stock outstanding 33.9M Shares fully diluted (incl. stock options, convertible notes*, and warrants) * June 26, 2023: See Form 8-K filed on June 26, 2023, at https://www.sec.gov/edgar/search/ January 2023: https://www.sec.gov/ix?doc=/Archives/edgar/data/0001069308/000119312523019802/d427052d8k.htm March 2022: https://www.sec.gov/ix?doc=/Archives/edgar/data/0001069308/000119312522066842/d279077d8k.htm Historical Gross proceeds Through June 22, 2023 $116.6M equity financings $35.0M from Relief Collaboration $20.5M from debt financings* $172.1M

Thank You www.acertx.com